ACC House Call: Saturday Late-Breaker Data

March 28, 2020
Kevin Kunzmann

A board member of the college highlights 4 highly anticipated trials coming out of ACC 2020.

The first day of virtual presentations from the ACC.20 Together with Word Congress of Cardiology (ACC/WCC) Scientific Sessions this Saturday is highlighted by a series of late-breaking trial data that could advance the levels of prevention, care, research, and rhetoric surrounding cardiometabolic and cardiovascular health.

In a special-edition House Call interview with HCPLive®, B. Hadley Wilson, Executive Vice Chair of Atrium Health Sanger Heart and Vascular Institute, ACC Board of Trustees member and Chair of the Membership Committee, previewed a quartet of new late-breaking trials he anticipates will highlight ACC 2020.

Wilson discussed pooled phase 3 inclisiran data for the reduction of LDL cholesterol (LDL-C), findings of a new combined-factor test for lifetime cardiovascular disease risk, new insights of the COMPASS trial assessing antiplatelet-anticoagulation combination therapy in diabetes, and results from the low-dose colchicine cost-effectiveness trial for cardiovascular outcomes post-myocardial infarction (COLCOT).